"It is exciting to share our experiences and the clinical outcomes from Ranger® with the nternational audience at the FESSH Congress.” Dr. Gregory Buncke, The Buncke Clinic
Alachua, FL (PRWEB) June 18, 2014
AxoGen, Inc. (NASDAQ: AXGN), a leading medical technology company focused on the peripheral nerve repair market, today announced the acceptance of two clinical presentations on the use of Avance® Nerve Graft and a scientific presentation on the use of coaptation aids in nerve repair at the 29th Congress of the Federation of European Societies for Surgery of the Hand (FESSH), June 18-21, 2014 in Paris, France. In addition, the Company will be exhibiting its full portfolio of nerve repair products at FESSH Booth 35.
Dr. Gregory Buncke, Director of The Buncke Clinic in San Francisco, will present “Outcomes from the Expanded Enrollment and Additions of Contemporary Controls for a Multicenter Registry Study Utilizing Processed Nerve Allografts” on Friday, June 20. The outcomes are from an expanded data set from the Ranger® Study, a multicenter, observational registry in peripheral nerve repair, and will include outcomes on the use of Avance® Nerve Graft across a range of nerve injuries in the hand and upper extremity.
In addition, a poster entitled, “Utilization of Coaptation Aids to Augment Peripheral Nerve Repairs: Quantitative Outcomes from a Multicenter Registry Study of Processed Nerve Allografts” will present clinical results using coaptation aids to facilitate tissue alignment, protect the nerve from the wound bed, and avoid tension at the repair site.
Finally, Erick DeVinney, Vice President of Clinical and Translational Sciences at AxoGen will give a presentation entitled, “In vivo evaluation of porcine small intestine submucosa based extracellular matrix nerve connector as an alternative to reconstituted collagen tube or direct suture repair in a sciatic nerve model” on Friday, June 20. This presentation will discuss the performance of AxoGuard® Nerve Connector, a porcine submucosa extracellular matrix (“ECM”) coaptation aid for tensionless repair of severed nerves.
“The Ranger® Study is now the largest multicenter clinical study in peripheral nerve repair and it has been influential in helping surgeons in the US understand the clinical outcomes of processed nerve allograft in sensory and motor repairs,” offered Dr. Buncke. “AxoGen’s portfolio of nerve repair products, especially Avance® Nerve Graft, has made it easier for our group to surgically repair severe nerve injuries and it is exciting to share our experiences and the clinical outcomes from Ranger® with the international audience at the FESSH Congress.”
The Congress is organized by FESSH, an organization which represents national hand surgery societies in Europe and seeks to define the highest standards for hand surgery throughout Europe, to implement and sustain study and research, and to identify optimal training programs.
About AxoGen, Inc.
AxoGen (NASDAQ: AXGN) is a leading medical technology company dedicated to peripheral nerve repair. AxoGen's portfolio of regenerative medicine products is available in the United States, Canada and several European countries and includes Avance® Nerve Graft, the only off-the-shelf commercially available processed nerve allograft for bridging severed nerves without the comorbidities associated with a second surgical site, AxoGuard® Nerve Connector, a porcine submucosa extracellular matrix ("ECM") coaptation aid for tensionless repair of severed nerves, and AxoGuard® Nerve Protector, a porcine submucosa ECM product used to wrap and protect injured peripheral nerves and reinforce the nerve reconstruction while preventing soft tissue attachments.
Avance® Nerve Graft is processed in the United States by AxoGen. AxoGuard® Nerve Connector and AxoGuard® Nerve Protector are manufactured in the United States by Cook Biotech Incorporated, and are distributed exclusively by AxoGen. AxoGen maintains its corporate offices in Alachua, Florida and is the parent of its wholly owned operating subsidiary, AxoGen Corporation.
To receive email alerts directly from AxoGen, please click here http://www.axogeninc.com/emailalerts.html.
Cautionary Statements Concerning Forward-Looking Statements
This Press Release contains "forward-looking" statements as defined in the Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations or predictions of future conditions, events or results based on various assumptions and management's estimates of trends and economic factors in the markets in which we are active, as well as our business plans. Words such as "expects", "anticipates", "intends", "plans", "believes", "seeks", "estimates", "projects", "forecasts", "continue", "may", "should", "will" variations of such words and similar expressions are intended to identify such forward-looking statements. The forward-looking statements may include, without limitation, statements regarding product commercialization and marketing efforts for its portfolio of peripheral nerve repair products, Avance® Nerve Graft, AxoGuard® Nerve Connector and AxoGuard® Nerve Protector, product development, financial performance, sales growth, product adoption, market awareness of our products, data validation and the intent to list on a national securities exchange. The forward-looking statements are subject to risks and uncertainties, which may cause results to differ materially from those set forth in the statements. Forward-looking statements in this release should be evaluated together with the many uncertainties that affect AxoGen's business and its market, particularly those discussed in the risk factors and cautionary statements in AxoGen's filings with the Securities and Exchange Commission. Forward-looking statements are not guarantees of future performance, and actual results may differ materially from those projected. The forward-looking statements are representative only as of the date they are made, and AxoGen assumes no responsibility to update any forward-looking statements, whether as a result of new information, future events or otherwise.
Source: AxoGen, Inc.